With our focus now firmly set on developing cannabinoid drugs for the pharmaceutical market, we have taken the decision to change our name to Ananda Pharma to reflect this approach. With best in class academic and industry partners, we are excited to deliver growth to shareholders and efficacious drugs to patients in need.
Ananda Pharma Plc
Pharmaceutical Manufacturing
London, England 1,628 followers
AQSE-listed company whose ambition is to be a leading provider of cannabinoid medicines for chronic pain conditions.
About us
Developer of cannabinoid-based medicines for the treatment of complex, chronic, inflammatory pain conditions. Patent pending formulation being used in two fully funded Phase II RCTs at Edinburgh University. Sale of two cannabidiol formulations through UK based medical cannabis pharmacy networks. Please contact for more info.
- Website
-
https://investors.anandadevelopments.com/s/f61f42
External link for Ananda Pharma Plc
- Industry
- Pharmaceutical Manufacturing
- Company size
- 2-10 employees
- Headquarters
- London, England
- Type
- Public Company
- Founded
- 2018
- Specialties
- research, science, and medicalcannabis
Locations
-
Primary
60 Gracechurch Street
London, England, GB
Employees at Ananda Pharma Plc
Updates
-
💯
🍃 New research points to potential of cannabinoids in gynaecological conditions 🍃 The former British Monarch, Queen Victoria, is thought to have relied on cannabis tinctures to manage her menstrual cramps. Now, after decades of strict regulation significantly restricting research into its therapeutic properties, science may be catching up. A recent study found CBD suppositories ‘significantly reduced frequency and severity of menstrual-related symptoms’, as well as their impact on daily functioning. While researchers at the University of Edinburgh say CBD is a “promising therapeutic agent” in the treatment of endometriosis. 💬 Dr Staci Gruber, director of the Cognitive and Clinical Neuroimaging Core and Marijuana Investigations for Neuroscientific Discovery (MIND) programme and Women's Health Initiative at McLean Hospital, says: “We know that there is tremendous potential [for cannabinoids] in pain and inflammation... We should be exploring some of these compounds to try to understand how to give individuals more relief.” 💬 Melissa Sturgess, CEO of Ananda Developments Plc adds: "We are one of the first to start doing clinical trials [of CBD] in endometriosis, but there is so much evidence to suggest that CBD will be effective." Read the full story: https://lnkd.in/ePmngw5R
-
Ananda is pleased to announce that it has raised £150,000 in additional funds from two private investors. The investors approached the Company and are looking forward to supporting Ananda long term. To read the full announcement and watch a summary video from Ananda's FD, Jeremy Sturgess-Smith, click the link below. https://lnkd.in/eH4DwdA7 Melissa Sturgess Jeremy Sturgess-Smith
AQSE:ANA - Ananda Developments - Subscription to raise £150,000
investors.anandadevelopments.com
-
Ananda is pleased to announce some exciting data from its heart failure programme. We have shown in mice that MRX1 significantly reduces the levels of a key heart failure biomarker! To watch an explainer video by Jeremy Sturgess-Smith and to read the full RNS, click here: https://lnkd.in/ePT-Uu84 #ANA #AQUIS #heart #failure #HFpEF #data Melissa Sturgess
-
Ananda is pleased to announce that it has passed a number of key stability milestone, a key step in its preparations for clinical trials. To read the full announcement, watch a summary video by Jeremy Sturgess-Smith and ask questions of management, click the link below. https://lnkd.in/ekUiAF_e #ANA #AQUIS #CBD #ClinicalTrials #chronicpain #endometriosis'
Ananda Developments investor hub
investors.anandadevelopments.com
-
Ananda Pharma Plc reposted this
Ananda Developments Plc is leading two major NHS-backed trials on cannabinoid medicines for epilepsy, aiming to expand CBD use beyond rare conditions. Despite concerns about #CBD isolates and strict trial protocols, Ananda focuses on meeting regulatory standards to advance access and evidence. Additional trials in Australia and the UK further explore its compounds. https://lnkd.in/eYEAjdh7
Ananda Aiming to 'Meet Regulators at Their Point of Need' As it Secures More Major UK Clinical Cannabis Trials - Business of Cannabis
businessofcannabis.com
-
Ananda Pharma Plc reposted this
Ananda set for heightened industry interest as clinical trials advance - broker @AnandaPlc #AQSE #ANA. Success in clinical trials, using Ananda Developments Plc's (AQSE:ANA) cannabinoid formulations, could generate significant industry and clinical interest, according to broker SP Angel. Liam Gascoigne-Cohen, analyst at SP Angel, in a recent research note highlighted that the planned trials would represent a significant validation of Ananda’s science-led approach and, significantly, that the Aquis quoted small-cap’s progress to date is “not fully captured” by the company market valuation. A note, following news that multiple Ananda-developed formulations would... http://ow.ly/QQY2105PAwS
-
Our CEO, Melissa Sturgess, recently delivered an update presentation via Investor Meet Company. The presentation highlighted our involvement in the recently announced Phase III epilepsy studies, where we are supplying two patent-pending drugs. It also covered the growing demand for cannabinoid medicines, projected approvals of cannabinoid drugs, and included a Q&A session with the audience. Click the link below to watch the update and get involved by asking your own questions: https://lnkd.in/erS8x8hw #ANA #presentation #AQUIS #smallcap #CBD #update Aquis Exchange
AQSE:ANA - Interim Update
investors.anandadevelopments.com
-
Ananda Pharma Plc reposted this
Join ANANDA DEVELOPMENTS PLC Interim Results TOMORROW at 12:30pm GMT. Click below to join https://lnkd.in/d9NQ77TA